Clinically meaningful improvements
in arm function

Patients with later-onset (Types 2 and 3) spinal muscular atrophy (SMA) treated with SPINRAZA® (nusinersen) achieved greater improvements in upper limb function compared with untreated patients.1

Change from baseline in RULM total score at month 151

Chart showing patients treated with SPINRAZA had an increase in RULM score over time
Chart showing patients treated with SPINRAZA had an increase in RULM score over time


Baseline:
SPINRAZA: 19.4
Untreated: 18.4

LSM=least squares mean; RULM=Revised Upper Limb Module; SE=standard error.

The mean RULM score at baseline was 19.4 for SPINRAZA compared with 18.4 for untreated patients out of a maximum score of 37.1

Claire
age 19

Later-onset (Type 2) SMA
treated with SPINRAZA

Claire
age 19

Later-onset (Type 2) SMA
treated with SPINRAZA

Individual results may vary based on several factors, including severity of disease, initiation of treatment, and duration of therapy.